Related Experiment Video
Updated: Jul 20, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Modeling prostate specific antigen kinetics in patients on active surveillance
Liying Zhang1, Andrew Loblaw, Laurence Klotz
1Division of Clinical Trials and Epidemiology, and Department of Radiation Oncology, and Division of Urology, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
The Journal of Urology
|September 6, 2006
Summary
Prostate specific antigen doubling time helps stratify patients into low and high risk groups for disease progression. This model aids in making informed decisions about treatment interventions during watchful waiting surveillance.
Area of Science:
- Urology
- Oncology
- Medical Statistics
Background:
- Prostate cancer management often involves active surveillance for favorable-risk cases.
- Monitoring prostate specific antigen (PSA) kinetics is crucial for assessing disease progression risk.
- Stratifying patients based on PSA dynamics aids in personalized treatment decisions.
Purpose of the Study:
- To stratify patients into low and high risk groups for prostate cancer progression using PSA doubling time.
- To model the PSA kinetics in these distinct risk groups.
- To inform decision-making for definitive intervention during surveillance.
Main Methods:
- Prospective, single-arm cohort study of patients with favorable clinical parameters.
- Conservative management with watchful waiting and serial PSA measurements.
- General linear mixed model used to estimate PSA evolution and calculate PSA doubling times.
Main Results:
- 231 patients with adequate follow-up were analyzed.
- 93 patients were classified as high-risk and 138 as low-risk based on PSA doubling time and biopsy.
- Average PSA doubling time was 2.97 years for high-risk and 6.54 years for low-risk groups.
Conclusions:
- A dynamic prognostic rule combining PSA doubling time and serial biopsy aids risk stratification.
- This approach enables rational decision-making for definitive intervention approximately 2.3 years after initiating surveillance.
- Optimized intervention timing based on individual risk profiles can be achieved.
